Marinaro Christina, Sauer John, Natale Christopher A, Ridky Todd, Chen Suzie
Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, The State University of New Jersey, New Brunswick, New Jersey, USA.
U.S. Department of Veterans Affairs, East Orange, New Jersey, USA.
Pigment Cell Melanoma Res. 2025 Jan;38(1):e13197. doi: 10.1111/pcmr.13197. Epub 2024 Sep 16.
Melanoma is the most aggressive and deadly form of skin cancer that arises from the transformation of melanocytes, the pigment producing cells of the skin. In the year 2024 there will be approximately 10,000 new cases of melanoma diagnosed and approximately 8,000 deaths attributed to melanoma in the United States. In this study we treated a group of male and female transgenic mice that spontaneously develop metastatic melanoma, TGS, with a G-protein-coupled estrogen receptor agonist LNS8801 to assess the efficacy on disease progression. A second group of male and female TGS mice was also exposed to UVB irradiation to mimic exposure to sunlight. Over the course of the 32-week experiment, visible images were taken by the small animal imaging IVIS system to track tumor progression, and blood and tissue samples were collected for molecular analyses. Results showed that sex-biased effects were observed in the efficacy of LNS8801 and that LNS8801 shows a UV-protective influence in both male and female TGS mice.
黑色素瘤是最具侵袭性和致命性的皮肤癌形式，它由黑素细胞（皮肤中的色素生成细胞）转变而来。2024年，美国预计将有大约10000例新诊断的黑色素瘤病例，约8000人死于黑色素瘤。在本研究中，我们用一种G蛋白偶联雌激素受体激动剂LNS8801治疗了一组自发发生转移性黑色素瘤的转基因小鼠（TGS），以评估其对疾病进展的疗效。另一组雄性和雌性TGS小鼠也接受了UVB照射，以模拟阳光照射。在为期32周的实验过程中，通过小动物成像IVIS系统拍摄可见图像以跟踪肿瘤进展，并采集血液和组织样本进行分子分析。结果表明，LNS8801的疗效存在性别差异，并且LNS8801在雄性和雌性TGS小鼠中均显示出紫外线防护作用。
